Document is current
Any future updates will be listed below
-
Authors
Luppi, Andrea I. https://orcid.org/0000-0002-3461-6431
Mediano, Pedro A. M. https://orcid.org/0000-0003-1789-5894
Rosas, Fernando E. https://orcid.org/0000-0001-7790-6183
Holland, Negin
Fryer, Tim D.
O’Brien, John T. https://orcid.org/0000-0002-0837-5080
Rowe, James B. https://orcid.org/0000-0001-7216-8679
Menon, David K. https://orcid.org/0000-0002-3228-9692
Bor, Daniel
Stamatakis, Emmanuel A. https://orcid.org/0000-0001-6955-9601
-
Funding
Funding for this research was provided by:
Gates Cambridge Trust (OPP1144)
Wellcome Trust (210920/Z/18/Z, 103838, 103838, 210920/Z/18/Z)
Ad Astra Chandaria Foundation
Patrick Berthoud Charitable Trust (RG99368, RG99368)
Cambridge University Centre for Parkinson-Plus
DH | National Institute for Health Research (146281, Senior Investigator Award)
RCUK | Medical Research Council (MR/M009041/1)
Canadian Institute for Advanced Research (RCZB/072 RG93193, RCZB/072 RG93193)
Canadian Institute for Advanced Research
Queens’ College Cambridge (Stephen Erskine Fellowship).
- License Information
-
More Information
Article History
Received: 20 November 2020
Accepted: 30 March 2022
First Online: 26 May 2022
Competing interests
: J.B.R. is a non-remunerated trustee of the Guarantors of Brain and the PSP Association (United Kingdom). J.B.R. provides consultancy to Asceneuron, Biogen and UCB and has research grants from AstraZeneca/MedImmune, Janssen and Lilly as industry partners in the Dementias Platform UK. All other authors declare no competing interests.
